by Richard Daverman, PhD
February 20, 2014 -- Lee’s Pharma has in-licensed China Rights to tafoxiparin, a clinical-stage product from Dilafor AB of Sweden. Tafoxiparin is a heparin derivative that has completed a Phase II trial as a treatment to induce labor. Lee’s will be responsible for conducting Phase II and III trials of the drug in China. Specific financial terms of the deal were not disclosed. More details....
Stock Symbol: (HK: 950)
Help employers find you! Check out all the jobs and post your resume.
